References
- Tseng S-T, et al. Clinical manifestations in uveitis patients with and without rheumatic disease in a Chinese population in Taiwan. J Microbiol Immunol Infect. 2017 Dec;50(6):798-804
- Guly CM, Forrester JV. Investigation and management of uveitis. BMJ 2010;341:959-8138
- Mayo Clinic. Uveitis: Causes. 2015. Available at: http://www.mayoclinic.org/diseases-conditions/uveitis/basics/causes/con-20026602 [Last accessed 18 May 2017]
- Standardization of Uveitis Nomenclature Working Group. Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop. Am J Ophthalmol 2005;140:509-16
- Mayo Clinic. Uveitis: Symptoms. 2015. Available at: http://www.mayoclinic.org/diseases-conditions/uveitis/basics/symptoms/con-20026602 [Last accessed 18 May 2017]
- Acharya NR, Tham VM, Esterberg E, et al. Incidence and prevalence of uveitis: results from the Pacific Ocular Inflammation Study. JAMA Ophthalmol 2013;131:1405-12
- Gritz DC, Wong IG. Incidence and prevalence of uveitis in Northern California: the Northern California epidemiology of uveitis study. Ophthalmology 2004;111:491-500
- Siddique SS, Suelves AM, Baheti U, Foster CS. Glaucoma and uveitis. Survey Ophthalmol 2013;58:1-10
- American Optometric Association. Optometric Clinical Practice Guideline: Care of the Patient with Anterior Uveitis. 1994. Available at: http://www.aoa.org/documents/optometrists/CPG-7.pdf [Last accessed 3 November 2016]
- Kempen JH, Altaweel MM, Holbrook JT, et al. Randomized comparison of systemic anti-inflammatory therapy versus fluocinolone acetonide implant for intermediate, posterior, and panuveitis: the multicenter uveitis steroid treatment trial. Ophthalmology 2011;118:1916-26
- Gopalakrishnan S, Ganeshkumar P. Systematic reviews and meta-analysis: understanding the best evidence in primary healthcare. J Fam Med Prim Care 2013;2:9
- Abdulaal M, Antonios R, Barikian A, et al. Etiology and clinical features of ocular inflammatory diseases in a tertiary center in Lebanon. Ocul Immunol Inflamm 2015;23:271-7
- Benoilid A, Tilikete C, Collongues N, et al. Relapsing optic neuritis: a multicentre study of 62 patients. Mult Scler J 2014;20:848-53
- Borrás-Blasco J, Castera D-E, Cortes X, et al. Effectiveness of infliximab, adalimumab and golimumab for non-infectious refractory uveitis in adults. Int J Clin Pharmacol Therapeut 2015;53:377-90
- Chu DS, Johnson SJ, Mallya UG, et al. Healthcare costs and utilization for privately insured patients treated for non-infectious uveitis in the USA. J Ophthalmic Inflammation Infection 2013;3:64
- Collier SA, Gronostaj MP, MacGurn AK, et al. Estimated burden of keratitis – United States, 2010. Morbidity Mortality Weekly Rep 2014;63:1027-30
- Dick AD, Tugal-Tutkun I, Foster S, et al. Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials. Ophthalmology 2013;120:777-87
- Dick AD, Tundia N, Sorg R, et al. Risk of ocular complications in patients with noninfectious intermediate uveitis, posterior uveitis, or panuveitis. Ophthalmology 2016;123:655-62
- Esterberg E, Acharya NR. Corticosteroid-sparing therapy: practice patterns among uveitis specialists. J Ophthalmic Inflammation Infection 2012;2:21-8
- Friedman DS, Holbrook JT, Ansari H, et al. Risk of elevated intraocular pressure and glaucoma in patients with uveitis: results of the multicenter uveitis steroid treatment trial. Ophthalmology 2013;120:1571-9
- Gui W, Dombrow M, Marcus I, et al. Quality of life in patients with noninfectious uveitis treated with or without systemic anti-inflammatory therapy. Ocul Immunol Inflamm 2015;23:135-43
- Hedayatfar A, Hashemi H, Asgari S, Chee S-P. Comparison of efficacy and ocular surface toxicity of topical preservative-free methylprednisolone and preserved prednisolone in the treatment of acute anterior uveitis. Cornea 2014;33:366-72
- Heo J, Sepah YJ, Yohannan J, et al. The role of biologic agents in the management of non-infectious uveitis. Expert Opin Biol Ther 2012;12:995-1008
- Jiménez-Balderas FJ, Fernandez-Arrieta G, Camargo-Coronel A, et al. Uveitis in adult patients with rheumatic inflammatory autoimmune diseases at a tertiary-care hospital in Mexico City. J Rheumatol. 2011 Feb;38(2):325-30
- Kaleemunnisha S, Sudharshan S, Biswas J. Quality of life in non-infectious uveitis patients on immunosuppressive therapy. Middle East African J Ophthalmol 2014;21:225
- Kheir V, Vaudaux J, Guex-Crosier Y. Review of the latest systemic treatments for chronic non-infectious uveitis. Expert Rev Ophthalmol 2016;11:111-33
- Leder HA, Jabs DA, Galor A, et al. Periocular triamcinolone acetonide injections for cystoid macular edema complicating noninfectious uveitis. Am J Ophthalmol 2011;152:441-8.e2
- Lee SH, Chung H, Yu HG. Clinical outcomes of cyclosporine treatment for noninfectious uveitis. Korean J Ophthalmol 2012;26:21-5
- Lightman S, Belfort R, Naik RK, et al. Vision-related functioning outcomes of dexamethasone intravitreal implant in noninfectious intermediate or posterior uveitis. Investig Ophthalmol Vis Sci 2013;54:4864-70
- Lowder C, et al. Dexamethasone intravitreal implant for noninfectious intermediate or posterior uveitis. Arch Ophthalmol 2011;129:545-53
- Naik RK, Rentz AM, Foster CS, et al. Normative comparison of patient-reported outcomes in patients with noninfectious uveitis. JAMA Ophthalmol 2013;131:219-25
- Parekh A, Srivastava S, Bena J, et al. Risk factors associated with intraocular pressure increase in patients with uveitis treated with the fluocinolone acetonide implant. JAMA Ophthalmol 2015;133:568-73
- Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmol 2010;117:567-75.e1
- Pleyer U, Thurau SR. Sirolimus for the treatment of noninfectious uveitis. Expert Opin Pharmacother 2016;17:127-35
- Prete M, Guerriero S, Dammacco R, et al. Autoimmune uveitis: a retrospective analysis of 104 patients from a tertiary reference center. J Ophthalmic Inflammation Infection 2014;4:17
- Rahimi M, Shahrzad SS, Banifatemi M. Comparison of intravitreal injection of bevacizumab and triamcinolone acetonide in the treatment of uveitic macular edema. Iranian J Immunol 2012;9:136-44
- Rathinam SR, Babu M, Thundikandy R, et al. A randomized clinical trial comparing methotrexate and mycophenolate mofetil for noninfectious uveitis. Ophthalmology 2014;121:1863-70
- Roesel M, Heinz C, Koch JM, Heiligenhaus A. et al. Comparison of orbital floor triamcinolone acetonide and oral prednisolone for cataract surgery management in patients with non-infectious uveitis. Graefe’s Arch Clin Exp Ophthalmol 2010;248:715-20
- Roesel M, Ruttig A, Schumacher C, et al. Smoking complicates the course of non-infectious uveitis. Graefe’s Arch Clin Exp Ophthalmol 2011;249:903-7
- Salek SS, Leder HA, Butler NJ, et al. Periocular triamcinolone acetonide injections for control of intraocular inflammation associated with uveitis. Ocul Immunol Inflamm 2013;21:257-63
- Sangwan VS, Pearson PA, Paul H, Comstock TL. Use of the fluocinolone acetonide intravitreal implant for the treatment of noninfectious posterior uveitis: 3-year results of a randomized clinical trial in a predominantly Asian population. Ophthalmol Ther 2015;4:1-19
- Saraiya NV, Goldstein DA. Dexamethasone for ocular inflammation. Expert Opin Pharmacother 2011;12:1127-31
- Sepah YJ, Michelle EH, Metcalf B, et al. Voclosporin: a potentially promising therapeutic agent for noninfectious uveitis. Expert Rev Ophthalmol 2011;6:281-6
- Sugar EA, Holbrook JT, Kempen JH, et al. Cost-effectiveness of fluocinolone acetonide implant versus systemic therapy for noninfectious intermediate, posterior, and panuveitis. Ophthalmology 2014;121:1855-62
- Multicenter Uveitis Steroid Treatment Trial Research Group. The multicenter uveitis steroid treatment trial: rationale, design, and baseline characteristics. Am J Ophthalmol 2010;149:550-61.e10
- Thorne JE, Skup M, Tundia N, et al. Direct and indirect resource use, healthcare costs and work force absence in patients with non‐infectious intermediate, posterior or panuveitis. Acta Ophthalmol 2016;94:e331-9
- Yu T, Holbrook JT, Thorne JE, et al. Outcome preferences in patients with noninfectious uveitis: results of a best–worst scaling study. Investig Ophthalmol Vis Sci 2015;56:6864-72
- Yu T, Holbrook JT, Thorne JE, Puhan MA. Using a patient‐centered approach to benefit–harm assessment in treatment decision‐making: a case study in uveitis. Pharmacoepidemiol Drug Saf 2016;25:363-71
- Zarranz-Ventura J, Carreño E, Johnston RL, et al. Multicenter study of intravitreal dexamethasone implant in noninfectious uveitis: indications, outcomes, and reinjection frequency. Am J Ophthalmol 2014;158:1136-45.e5
- Shaw J. Immunosuppression in Uveitis: Finding the Balance. 2011. Available at: http://www.aao.org/eyenet/article/immunosuppression-in-uveitis-finding-balance [Last accessed 29 December 2016]
- Jaffe GJ, Dick AD, Brézin AP, et al. Adalimumab in patients with active noninfectious uveitis. N Engl J Med 2016;375:932-43
- Nguyen QD, Merrill PT, Jaffe GJ, et al. Adalimumab for prevention of uveitic flare in patients with inactive non-infectious uveitis controlled by corticosteroids (VISUAL II): a multicentre, double-masked, randomised, placebo-controlled phase 3 trial. Lancet 2016;388:1183-92